V
ENVB icon

Veritable’s Enveric Biosciences ENVB Stock Holding History

Veritable’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$4K – 829
2022
Q2 		$4K Buy
+2
New +$4.25K ﹤0.01% 906

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Veritable's ENVB Position: Q3 2022 in Review

Veritable sold out of Enveric Biosciences (ENVB) in Q3 2022, closing a stake of 2 shares — an estimated $4K sold.

Veritable first reported a position in ENVB in Q2 2022 and held it in 1 quarter. The position peaked at $4K in Q2 2022. 9 funds tracked by Wall St. Rank hold ENVB as of Q3 2022.

  • Veritable reported no remaining Enveric Biosciences position as of Q3 2022 after selling out during the quarter.
  • Veritable sold 2 Enveric Biosciences shares in Q3 2022, an estimated $4K.
  • Veritable first reported a position in Enveric Biosciences in Q2 2022 and held it in 1 quarter.
  • Veritable's Enveric Biosciences position peaked at $4K in Q2 2022.
  • 9 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.